Kaposi Sarcoma Among People Living with HIV in the French DAT'AIDS Cohort Between 2010 and 2015

Overview

Journal J Eur Acad Dermatol Venereol

Specialty Infectious Diseases

Date 2020 Jan 19

PMID 31953902

Citations 2

Authors

I Poizot-Martin

V Obry-Roguet

C Duvivier

C Lions

T Huleux

C Jacomet

T Ferry

A Cheret

C Allavena

F Bani-Sadr

R Palich

A Cabie

A Fresard

P Pugliese

P Delobel

I Lamaury

L Hustache-Mathieu

S Bregigeon

A Makinson

D Rey

Affiliations

Soon will be listed here.

Abstract

Background: Although antiretroviral therapy (ART) has reduced the risk of Kaposi sarcoma (KS), KS cases still occur in HIV-infected people.

Objective: To describe all KS cases observed between 2010 and 2015 in a country with high ART coverage.

Methods: Retrospective study using longitudinal data from 44 642 patients in the French Dat'AIDS multicenter cohort. Patients' characteristics were described at KS diagnosis according to ART exposure and to HIV-plasma viral load (HIV-pVL) (≤50 or >50) copies/mL.

Results: Among the 209 KS cases diagnosed during the study period, 33.2% occurred in ART naïve patients, 17.3% in ART-experienced patients and 49.5% in patients on ART, of whom 23% for more than 6 months. Among these patients, 24 (11.5%) had HIV-pVL ≤50 cp/mL, and 16 (66%) were treated with a boosted-PI-based regimen. The distribution of KS localization did not differ by ART status nor by year of diagnosis.

Limitations: Data on human herpesvirus 8, treatment modalities for KS and response rate were not collected.

Conclusion: Half of KS cases observed in the study period occurred in patients not on ART, reflecting the persistence of late HIV diagnosis. Factors associated with KS in patients on ART with HIV-pVL ≤50 cp/mL remain to be explored.

Citing Articles

HIV-1 Tat-induced disruption of epithelial junctions and epithelial-mesenchymal transition of oral and genital epithelial cells lead to increased invasiveness of neoplastic cells and the spread of herpes simplex virus and cytomegalovirus.

Tugizov S Front Immunol. 2025; 16:1541532.

PMID: 40018040 PMC: 11866325. DOI: 10.3389/fimmu.2025.1541532.

Kaposi Sarcoma in People Living with HIV: Is it Water under the Bridge?.

Papalini C, Brescini L, Curci L, Bastianelli S, Barchiesi F, Giacometti A Mediterr J Hematol Infect Dis. 2023; 15(1):e2023027.

PMID: 37180210 PMC: 10171203. DOI: 10.4084/MJHID.2023.027.

Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma.

Poizot-Martin I, Bregigeon S, Palich R, Marcelin A, Valantin M, Solas C Cancers (Basel). 2022; 14(4).

PMID: 35205734 PMC: 8869819. DOI: 10.3390/cancers14040986.

References

El-Mallawany N, McAtee C, Campbell L, Kazembe P . Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives. Pediatric Health Med Ther. 2018; 9:35-46. PMC: 5919159. DOI: 10.2147/PHMT.S142816. View

Yarchoan R, Uldrick T . HIV-Associated Cancers and Related Diseases. N Engl J Med. 2018; 378(11):1029-1041. PMC: 6890231. DOI: 10.1056/NEJMra1615896. View

Lebbe C, Garbe C, Stratigos A, Harwood C, Peris K, Del Marmol V . Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer. 2019; 114:117-127. DOI: 10.1016/j.ejca.2018.12.036. View

Palich R, Veyri M, Valantin M, Marcelin A, Guihot A, Pourcher V . Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. Clin Infect Dis. 2019; 70(11):2435-2438. DOI: 10.1093/cid/ciz762. View

OConnell S, Enkelmann J, Sadlier C, Bergin C . Late HIV presentation - missed opportunities and factors associated with a changing pattern over time. Int J STD AIDS. 2016; 28(8):814-821. DOI: 10.1177/0956462416674093. View

Zhou F, Xue M, Qin D, Zhu X, Wang C, Zhu J . HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3β signaling pathway. PLoS One. 2013; 8(1):e53145. PMC: 3534639. DOI: 10.1371/journal.pone.0053145. View

Wilton J, Light L, Gardner S, Rachlis B, Conway T, Cooper C . Late diagnosis, delayed presentation and late presentation among persons enrolled in a clinical HIV cohort in Ontario, Canada (1999-2013). HIV Med. 2018; 20(2):110-120. DOI: 10.1111/hiv.12686. View

Curtiss P, Strazzulla L, Friedman-Kien A . An Update on Kaposi's Sarcoma: Epidemiology, Pathogenesis and Treatment. Dermatol Ther (Heidelb). 2016; 6(4):465-470. PMC: 5120640. DOI: 10.1007/s13555-016-0152-3. View

Darling K, Hachfeld A, Cavassini M, Kirk O, Furrer H, Wandeler G . Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. Swiss Med Wkly. 2016; 146:w14348. DOI: 10.4414/smw.2016.14348. View

10.

Deblonde J, Van Beckhoven D, Loos J, Boffin N, Sasse A, Nostlinger C . HIV testing within general practices in Europe: a mixed-methods systematic review. BMC Public Health. 2018; 18(1):1191. PMC: 6196459. DOI: 10.1186/s12889-018-6107-0. View

11.

Chen X, Cheng L, Jia X, Zeng Y, Yao S, Lv Z . Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice. Neoplasia. 2009; 11(12):1272-84. PMC: 2794508. DOI: 10.1593/neo.09494. View

12.

Kowalkowski M, Kramer J, Richardson P, Suteria I, Chiao E . Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection. Clin Infect Dis. 2015; 60(9):1405-14. PMC: 4462659. DOI: 10.1093/cid/civ012. View

13.

Komninakis S, Mota M, Hunter J, Diaz R . Late Presentation HIV/AIDS Is Still a Challenge in Brazil and Worldwide. AIDS Res Hum Retroviruses. 2017; 34(2):129-131. DOI: 10.1089/AID.2015.0379. View

14.

Guihot A, Dupin N, Marcelin A, Gorin I, Bedin A, Bossi P . Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis. 2006; 194(8):1078-88. DOI: 10.1086/507648. View

15.

Krown S, Lee J, Dittmer D . More on HIV-associated Kaposi's sarcoma. N Engl J Med. 2008; 358(5):535-6. PMC: 2857919. DOI: 10.1056/NEJMc072994. View

16.

Saxena A, Netchiporouk E, Al-Rajaibi R, Billick R, Roshdy O . Iatrogenic Kaposi's sarcoma after immunosuppressive treatment for granulomatosis with polyangiitis (Wegener's). JAAD Case Rep. 2016; 1(2):71-3. PMC: 4802573. DOI: 10.1016/j.jdcr.2014.12.002. View

17.

Philibert P, Chiche L, Cailleres S, Allemand J, Rebaudet S, Delord M . HHV8 and Kaposi's sarcoma: should we really give up protease inhibitors in all HIV-infected patients?. AIDS. 2017; 31(15):2167-2169. DOI: 10.1097/QAD.0000000000001588. View

18.

Lions C, Cabras O, Cotte L, Huleux T, Gagneux-Brugnon A, Makinson A . Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort. BMC Infect Dis. 2019; 19(1):278. PMC: 6434788. DOI: 10.1186/s12879-019-3915-5. View

19.

Moore P, Chang Y . Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med. 1995; 332(18):1181-5. DOI: 10.1056/NEJM199505043321801. View

20.

Esson G, Holme S . HIV testing in dermatology - a national audit. Int J STD AIDS. 2017; 29(6):611-613. DOI: 10.1177/0956462417731679. View